Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 16/20 | 0.38 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693670 | 1.00 | PIM2 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL15873240 | 1.00 | PIM2 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL15873237 | 1.00 | PIM2 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL4433871 | 0.89 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL11899432 | 0.89 | MEN1 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL11898639 | 0.89 | MEN1 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL11898640 | 0.89 | MEN1 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL11899431 | 0.89 | MEN1 (0.38) | PIM2PIM1PIM3MEN1KMT2A | |
| SCHEMBL2833146 | 0.87 | PIM2 (0.36) | PIM2PIM1PIM3 | |
| SCHEMBL18430040 | 0.87 | PIM2 (0.36) | PIM2PIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3036238-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | Incyte Corporation (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015027124-A1 | FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS | INCYTE CORPORATION (US) | 2015-02-26 | — | — | WO | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| EP-2262802-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM1 1/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.